Prasenjit Maity

Prasenjit Maity

Auto-generated profile, based on publicly available information

Prasenjit Maity

Department of Pharmaceutical Sciences and Technology Birla Institute of Technology Mesra Jharkhand India

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 June 2025 in RSC Advances
Verified
Journal Article
Open access
PDF file
PMPrasenjit Maity
Prasenjit Maity
SGSwastika Ganguly
Swastika Ganguly
PDPran Kishore Deb
Pran Kishore Deb
All human cells contain the universal autocoid adenosine, which interacts with four types of G protein-coupled receptors (GPCRs), namely A1, A2A, A2B, and A3 adenosine receptors (ARs). Among these receptors, A2A and A2B ARs activate adenylate cyclase, while A1 and A3 ARs suppress the adenylate cyclase activity. Adenosine-receptor interactions play a crucial role in cancer biology by modulating the immune microenvironment, which tumors exploit to create immunosuppression that promotes their growth and metastasis. When the A2A AR is activated on natural killer (NK) cells and T cells, it reduces their ability to carry out cytotoxic functions. This activation also encourages the formation of immune-suppressing cell types, such as myeloid-derived suppressor cells (MDSCs) and regulatory T cells (Tregs), further weakening the immune response. Targeting adenosine receptors, particularly the A2A subtype, represents a promising therapeutic strategy. By antagonizing these receptors, it may be possible to restore T cell function, helping the body to recognize and attack cancer cells more effectively. Despite recent advancements in the discovery of novel, targeted anticancer agents, these treatments have shown limited effectiveness against metastatic tumours, complicating cancer management. Moreover, developing adenosine receptor agonists or antagonists with high target selectivity and potency remains a significant challenge, as the widespread distribution of adenosine receptors throughout the body raises concerns about off-target effects and reduced therapeutic efficacy. In order to improve outcomes for patients with advanced cancer, researchers are actively investigating safer and more efficient chemotherapy substitutes. However, drugs that activate A3 adenosine receptors and block A2A receptors are being explored as a novel approach for cancer treatment. Monoclonal antibodies and small-molecule inhibitors targeting the CD39/CD73/A2A AR axis are also being tested in clinical trials, both as standalone treatments and in combination with anti-PD-1/PD-L1 immunotherapies. This review primarily focuses on the signaling pathways and the therapeutic potential of various adenosine receptor agonists and antagonists across various cancer types, highlighting their ongoing evaluation in preclinical and clinical trials, both as monotherapies and in rational combination with immunotherapy, chemotherapy, or targeted therapies, potentially leading to the development of advanced treatments that could aid in tumor suppression.

4 February 2026 in AAPS PharmSciTech
Verified
Journal Article
Closed access
PDF file
CSChandan Kumar Singh
Chandan Kumar Singh
RBRatnali Bania
Ratnali Bania
SDSatyendra Deka
Satyendra Deka
MDMonika Dwivedi
Monika Dwivedi
ANAnroop B. Nair
Anroop B. Nair
PDPran Kishore Deb
Pran Kishore Deb

23 July 2026 in Current Pharmaceutical Design
Verified
Journal Article
Closed access
PDF file
RMRaghu Prasad Mailavaram
Raghu Prasad Mailavaram
YCYogesh Chaudhari
Yogesh Chaudhari
RTRitesh S. Tarwani
Ritesh S. Tarwani
Katharigatta VenugopalaKatharigatta Venugopala
Katharigatta Venugopala
Manik GhoshManik Ghosh
Manik Ghosh
PDPran Kishore Deb
Pran Kishore Deb
Phosphodiesterase 4 (PDE4) facilitates the enzymatic breakdown of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP), through its four distinct isotypes, namely PDE4A to PDE4D, along with more than 25 splice variants. It plays a crucial role in cancer development, respiratory issues such as asthma and chronic obstructive pulmonary disease (COPD), autoimmune diseases like psoriasis, and neurological disorders such as Alzheimer’s disease. Various methods are being developed to enhance clinical efficacy and reduce side effects. Some of these methods include drug delivery via inhalation and the development of non-emetic PDE4 inhibitors and mixed PDE inhibitors. These inhibitors offer several advantages over traditional formulations, including selectivity for specific inhibitors, targeted tissue distribution, and oral effectiveness. All these efforts have led to the emergence of novel PDE4 inhibitors, with some having progressed to clinical trial stages and others approved as medications. This review summarises PDE4 inhibitors currently in clinical trials, highlighting their therapeutic potential, limitations, and future prospects.

16 February 2026 in Journal of Computational Biophysics and Chemistry
Verified
Journal Article
Closed access
VBVivek Bakshi
Vivek Bakshi
ACAmrita Chatterjee
Amrita Chatterjee
PMPrasenjit Maity
Prasenjit Maity
ACAnkit Chowdhury
Ankit Chowdhury
TSTanishk Saini
Tanishk Saini
PMPapiya Mitra Mazumder
Papiya Mitra Mazumder

20 August 2026 in ChemistrySelect
Verified
Journal Article
Open access
PDF file
RNRajarshi Nath
Rajarshi Nath
LDLakshminarayan Das
Lakshminarayan Das
ACArka Chakraborty
Arka Chakraborty
ACAnhic Chakraborty
Anhic Chakraborty
SHAH ALAM KHANSHAH ALAM KHAN
SHAH ALAM KHAN
MAMd Jawaid Akhtar
Md Jawaid Akhtar
Over the past several decades, extensive research has led to the development of inhibitors targeting α‐glucosidase, α‐amylase, and peroxisome proliferator–activated receptors (PPARγ) for the management of diabetes. However, the currently available antidiabetic drugs suffer from the limitations of toxicity and resistance, highlighting the need for safer and effective therapeutic agents. Six‐membered nitrogen‐containing heterocycles, their structural versatility and pharmacophoric features, exhibit diverse biological activities. The nitrogen atoms present in heterocyclic rings enhance the hydrogen‐bond interactions with key diabetes‐associated targets, thereby improving receptor binding and pharmacological performance. Recently published studies have increasingly focused on molecular hybridization strategies that incorporate nitrogen‐containing heterocycles into the core structures to yield new hybrid molecules that enhance insulin sensitivity while optimizing their efficacy and safety profiles. This review summarizes recent advances in synthetic methodologies, molecular modelling, and structure–activity relationship (SAR) analyses of nitrogen‐containing six‐membered heterocycles over the past 5 years (2020–25) targeting diabetes. The heterocyclic scaffolds discussed include the core six‐membered N ‐heterocycles such as triazine, pyridine, pyrimidine, piperidine, piperazine, and morpholine, along with their structurally diverse derivatives. Moreover, insights gained from these investigations provide a rational framework for the design and development of next‐generation antidiabetic agents with enhanced selectivity, reduced toxicity, and improved pharmacological profiles.